Palifermin

• Product Name:Palifermin
• Synonyms: palifermin 24-163-Keratinocyte growth factor (human) Kepivance 24-163 Fibroblast growth factor 7 (human) Unii-qms40680K6
• CAS:162394-19-6
• MF:
• MW:0
• EINECS:
• Mol File:Mol File
• 

Palifermin (trade name Kepivance, marketed by Biovitrum) is a truncated human recombinant keratinocyte growth factor (KGF)[1] produced in Escherichia coli. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract. When patients with blood cancers (leukemia and lymphoma) receive high dose chemotherapy and radiation therapy to undergo bone marrow transplantation, they usually get severe oral mucositis.[3] Palifermin reduces the incidence and duration of severe oral mucositis[4][5] by protecting those cells and stimulating the growth of new epithelial cells to build up the mucosal barrier. Palifermin is also being studied in the prevention and treatment of oral mucositis and dysphagia (difficulty swallowing) in other types of cancer.